Abstract

To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs). Patients who underwent targeted massively parallel sequencing of primary ECs between 2014 and 2018 and preoperative CE-CT were included (n = 150). Molecular subtypes of EC were assigned using DNA polymerase epsilon (POLE) hotspot mutations and immunohistochemistry-based p53 and MMR protein expression. TMB was derived from sequencing, with > 15.5 mutations-per-megabase as a cut-point to define TMB-H tumors. After radiomic feature extraction and selection, radiomic features and clinical variables were processed with the recursive feature elimination random forest classifier. Classification models constructed using the training dataset (n = 105) were then validated on the holdout test dataset (n = 45). Integrated radiomic-clinical classification distinguished MMR-D from copy number (CN)-low-like and CN-high-like ECs with an area under the receiver operating characteristic curve (AUROC) of 0.78 (95% CI 0.58–0.91). The model further differentiated TMB-H from TMB-low (TMB-L) tumors with an AUROC of 0.87 (95% CI 0.73–0.95). Peritumoral-rim radiomic features were most relevant to both classifications (p ≤ 0.044). Radiomic analysis achieved moderate accuracy in identifying MMR-D and TMB-H ECs directly from CE-CT. Radiomics may provide an adjunct tool to molecular profiling, especially given its potential advantage in the setting of intratumor heterogeneity.

Highlights

  • To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs)

  • The Cancer Genome Atlas (TCGA) has defined four molecular subtypes of EC that correlate with prognosis: DNA polymerase epsilon (POLE) mutant [ultramutated], microsatellite instability-high (MSI-H)/mismatch-repair deficient (MMR-D) [hypermutated], copy-number low (CNlow) [endometrioid-like], and copy-number high (CN-high) [serous-like]18

  • We aimed to evaluate whether radiomic analysis of contrast-enhanced computed tomography (CE-CT) obtained during initial staging of EC can identify MMR-D and TMB-H tumors

Read more

Summary

Introduction

To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs). Radiomic approaches that implement machine learning algorithms have already successfully uncovered a number of associations between radiomic signatures and key genomic drivers across several cancer t­ypes[2,3,4,5] This growing body of literature points to a latent opportunity to integrate imaging as a biomarker for new targeted ­therapies[6,7,8,9]. The FIGO system has limited prognostic relevance in uterine-confined ­disease[13], and there is interobserver-variability both in the pathologic assessment of tumor grade and in the diagnosis of high-grade ­ECs14–17 Beyond this histologic classification, The Cancer Genome Atlas (TCGA) has defined four molecular subtypes of EC that correlate with prognosis: DNA polymerase epsilon (POLE) mutant [ultramutated], microsatellite instability-high (MSI-H)/mismatch-repair deficient (MMR-D) [hypermutated], copy-number low (CNlow) [endometrioid-like], and copy-number high (CN-high) [serous-like]18. Radiomic analysis has the potential to simultaneously and non-invasively assess both primary and metastatic lesions, potentially capturing inter-lesion molecular heterogeneity

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call